Yervoy (ipilimumab) is a medication used to treat advanced melanoma, a type of skin cancer that has spread to other parts of the body. It is a type of immunotherapy that works by activating the immune system to attack cancer cells [3].

According to Drug Patent Watch [1], Yervoy is available in two dosage strengths, 50 mg and 200 mg, and the recommended dosage is based on the patient's weight. Patients who weigh less than 80 kg are usually prescribed a dose of 3 mg/kg, while those who weigh more than 80 kg are prescribed a dose of 200 mg.

However, the dosage of Yervoy can affect the severity of its side effects. Medical News Today [2] reports that Yervoy can cause a range of side effects, including fatigue, diarrhea, nausea, vomiting, loss of appetite, and skin rash. In some cases, it can also cause more serious side effects, such as inflammation of the colon, liver damage, and nerve damage.

The higher dosage of Yervoy, 200 mg, is associated with a higher incidence of side effects. In clinical trials, patients who received the 200 mg dose experienced more severe side effects than those who received the 50 mg dose [2]. However, it is important to note that the severity of side effects can vary from person to person, and some patients may experience severe side effects even with a lower dosage of Yervoy.

In conclusion, Yervoy dosage can affect the severity of its side effects. The higher dosage of Yervoy, 200 mg, is associated with a higher incidence of side effects, but the severity of side effects can vary from person to person. Patients should discuss the risks and benefits of Yervoy with their healthcare provider and report any side effects they experience during treatment.

Sources:
[1] https://www.drugpatentwatch.com/p/biologics/tradename/YERVOY
[2] https://www.medicalnewstoday.com/articles/drugs-yervoy-side-effects
[3] https://www.rxlist.com/yervoy-drug.htm